Bicocca Open Archive

Logo unimib boa
LUPPI, FABRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.587
EU - Europa 4.330
AS - Asia 2.932
SA - Sud America 27
AF - Africa 14
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 3
Totale 16.904
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.446
SG - Singapore 1.144
IT - Italia 1.112
IE - Irlanda 911
HK - Hong Kong 756
CN - Cina 665
RU - Federazione Russa 629
DE - Germania 526
SE - Svezia 478
GB - Regno Unito 213
UA - Ucraina 170
ID - Indonesia 167
CA - Canada 124
FR - Francia 84
VN - Vietnam 67
FI - Finlandia 44
NL - Olanda 33
IN - India 29
TR - Turchia 29
DK - Danimarca 28
AT - Austria 27
BE - Belgio 24
JP - Giappone 24
MX - Messico 17
BR - Brasile 15
CZ - Repubblica Ceca 12
CH - Svizzera 11
PK - Pakistan 10
AU - Australia 7
PH - Filippine 7
ES - Italia 6
IR - Iran 6
MN - Mongolia 6
RO - Romania 5
TW - Taiwan 5
AR - Argentina 4
CL - Cile 4
EG - Egitto 4
KR - Corea 4
NZ - Nuova Zelanda 4
EU - Europa 3
IL - Israele 3
MU - Mauritius 3
NG - Nigeria 3
PE - Perù 3
PL - Polonia 3
PT - Portogallo 3
BG - Bulgaria 2
MA - Marocco 2
MM - Myanmar 2
MT - Malta 2
SA - Arabia Saudita 2
TN - Tunisia 2
AL - Albania 1
AM - Armenia 1
CO - Colombia 1
GR - Grecia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
NO - Norvegia 1
NP - Nepal 1
RS - Serbia 1
TH - Thailandia 1
YE - Yemen 1
Totale 16.904
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.515
Fairfield 1.223
Singapore 1.015
Dublin 896
Hong Kong 756
Wilmington 595
Ashburn 540
Woodbridge 518
Seattle 501
Chandler 474
Frankfurt am Main 444
Houston 441
Cambridge 390
Princeton 370
Santa Clara 329
New York 323
Dearborn 272
Milan 255
Jakarta 167
Altamura 158
Nanjing 154
Jacksonville 147
Lawrence 139
Beijing 84
Shanghai 81
Ottawa 78
San Diego 76
Andover 65
Rome 56
Dong Ket 46
London 45
Boardman 41
Hebei 41
Shenyang 37
Helsinki 35
Fremont 34
Nanchang 33
Guangzhou 30
Monza 28
Toronto 28
Jiaxing 23
Jinan 22
Norwalk 21
Vienna 21
Brussels 20
Chicago 20
Hefei 19
Tianjin 18
Bari 17
Genoa 17
Kocaeli 17
Munich 16
Changsha 15
Lissone 15
Ningbo 13
Naples 11
Nuremberg 11
Bologna 10
Redmond 10
Saint Louis 10
Brno 9
Carate Brianza 9
Falls Church 8
Lappeenranta 8
Zurich 8
Amsterdam 7
Beauharnois 7
Castrolibero 7
Cesate 7
Palermo 7
Washington 7
Zhengzhou 7
Brescia 6
Casorate Primo 6
Catania 6
Desio 6
Gallarate 6
Laurel 6
Pune 6
Ankara 5
Duncan 5
Edmonton 5
Faisalabad 5
Fuzhou 5
Groningen 5
Kunming 5
Lodi 5
Los Angeles 5
New Bedfont 5
Padova 5
Taizhou 5
Turin 5
Acquafredda 4
Casier 4
Chiswick 4
Dallas 4
Hangzhou 4
Hanoi 4
Leawood 4
Manila 4
Totale 13.016
Salva come PNG Salva come JPEG
Nome #
Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers 291
Early referral to palliative care services in patients with IPF: A tool to take a step forward 277
Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study 235
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 218
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? 215
Janus-faced amiodarone-induced pneumopathy 202
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 200
Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential 191
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 180
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 179
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 177
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 175
Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis 169
Non-tuberculous mycobacteria pulmonary disease: an integrated approach beyond antibiotics 168
Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis 160
Clinical differences in sarcoidosis patients with and without lymphoma: A single-centre retrospective cohort analysis 156
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust 153
Cigarette smoke upregulates clusterin expression and apoptosis in human bronchial epithelial cells 150
Cigarette smoke extract (CSE) induces clusterion expression in human lung fibroblasts. 148
What patients with Idiopathic Pulmonary Fibrosis and caregivers want - Filling the currents gaps with patient reported outcomes and experience measures 147
Healthcare costs and resources utilization in children with difficult-to-control asthma treated with biologic therapies: A population-based cohort study 143
Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study 142
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 141
Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study 133
One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study 131
Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study 129
Nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis and right heart dysfunction: A prespecified subgroup analysis of a double-blind randomized clinical trial (instage) 126
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis 125
Diagnosis of asthma and copd 122
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 122
Best supportive care for idiopathic pulmonary fibrosis: Current gaps and future directions 116
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review 114
Acute exacerbation of idiopathic pulmonary fibrosis: Lessons learned from acute respiratory distress syndrome? 114
Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis 114
Management of fixed airflow limitation caused by asthma or chronic obstructive pulmonary disease 114
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment 113
Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study 112
Molecular biomarkers in idiopathic pulmonary fibrosis: State of the art and future directions 111
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 109
High serum levels of silica nanoparticles in systemic sclerosis patients with occupational exposure: Possible pathogenetic role in disease phenotypes 108
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 108
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 107
Management of Idiopathic Pulmonary Fibrosis 107
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 107
Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: A multicenter prospective study 105
Interstitial pneumonitis with autoimmune features (IPAF): A work in progress 105
Feasibility and clinical impact of a portable bi-level ventilation device in patients with severe chronic obstructive pulmonary disease and exertional dyspnea: preliminary results from a clinical series 105
Effects of cigarette smoke condensate on proliferation and wound closure of bronchial epithelial cells in vitro: role of glutathione 104
Evaluation of serum (1 → 3)-β-d-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors 103
The Multiple Components of COPD 102
Sarcoidosis: challenging diagnostic aspects of an old disease 101
Short-term Evolution of Nutritional Status in Patients with Idiopathic Pulmonary Fibrosis 100
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: A case report 99
Multidisciplinary approach to systemic diseases: benefits for diagnosis and management of complex disorders 99
Update in chronic obstructive pulmonary disease 2006 98
Mindfulness-based stress reduction in patients with interstitial lung diseases: A pilot, single-centre observational study on safety and efficacy 97
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases 97
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial 97
Clinical performance of a commercial real-time PCR assay for Aspergillus DNA detection in serum samples from high-risk patients: comparison with a galactomannan enzyme immunoassay 96
Update in chronic obstructive pulmonary disease 2005 96
Bronchial hyperresponsiveness in asthmatic adults - A long-term correlation study 96
Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation 96
Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic 95
Pulmonary comorbidities associated with chronic obstructive pulmonary disease | [BPCO e altre malattie polmonari croniche] 95
Six-Month Pulmonary Impairment after Severe COVID-19: A Prospective, Multicentre Follow-Up Study 95
A multidisciplinary approach to screen the post-COVID-19 conditions 93
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 93
Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases 92
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature 92
Complex chronic co-morbidities of COPD 91
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19 91
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 90
Definizione, classificazione ed eziopatogenesi 90
Pathophysiology of exacerbations of chronic obstructive pulmonary disease 88
Bradykinin-induced asthmatic fibroblast/myofibroblast activities via bradykinin B2 receptor and different MAPK pathways 88
Non-steroid agents for idiopathic pulmonary fibrosis 88
Lung complications of Sjogren syndrome 88
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 88
Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study 87
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 87
In vitro increase of epidermal growth factor receptor expression in the lung epithelial cells after exposure to cigarette smoke 87
Feasibility of CPAP application and variables related to worsening of respiratory failure in pregnant women with SARS-CoV-2 pneumonia: Experience of a tertiary care centre 87
Pathology of COPD and asthma 86
Clusterin (CLU) and lung cancer 86
Predicting the future of patients with idiopathic pulmonary fibrosis: another step forward 84
Management of idiopathic pulmonary fibrosis 84
EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to egfr inhibitors 84
The big clinical trials in idiopathic pulmonary fibrosis 84
Impact of N-acetyl-L-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study 84
To BAL or not to BAL: Is this a problem in diagnosing IPF? 83
Treatment of chronic obstructive pulmonary disease and its comorbidities 83
Prognostic role of clusterin in resected adenocarcinomas of the lung 83
Clusterin decreases oxidative stress in lung fibroblasts exposed to cigarette smoke 81
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells 81
Broncopneumopatia cronica ostruttiva: Patogenesi 80
Genetic testing in diffuse parenchymal lung disease 80
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows 80
Rheumatoid arthritis related interstitial lung disease 80
Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: A randomized noninferiority trial 78
Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation 77
Totale 11.738
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.259
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.259
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.375 0 0 0 0 0 0 347 287 289 179 157 116
2020/20212.858 86 172 472 354 309 234 206 286 146 233 155 205
2021/20221.845 154 208 190 193 90 120 84 124 98 95 160 329
2022/20232.726 417 725 264 172 169 468 38 134 166 24 84 65
2023/20242.467 55 66 93 76 330 607 547 85 281 33 35 259
2024/20253.632 400 1.168 430 326 609 308 391 0 0 0 0 0
Totale 17.875